Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2137023 | Leukemia Research | 2012 | 8 Pages |
Abstract
Imatinib mesylate, a Bcr/Abl tyrosine kinase inhibitor, is widely used in treating chronic myeloid leukemia. However, drug-resistance of leukemia cells becomes an emergent problem. Herein, various flavonoids were screened for applicability in leukemia treatment, and 3-hydroxyflavone (3-HF) was found to be most effective in reducing cancer cell viability. The combination of 3-HF and imatinib mesylate resulted in significant apoptotic cell death in imatinib mesylate-resistant leukemia cells. Combined treatment resulted in apparent activation of caspases and decrease of the oncoprotein phosphor-Bcr/Abl in leukemia cells. Our results suggest that this combined treatment is beneficial in imatinib mesylate-resistant chronic myelogenous leukemia.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Jung-Hyun Kim, Minjung Song, Geun-Ho Kang, Eung-Ryoung Lee, Hye-Yeon Choi, Chung Lee, Jin-Hoi Kim, Youngsoo Kim, Bon-Nyeo Koo, Ssang-Goo Cho,